| Literature DB >> 26087656 |
Dan Li1,2, XiaoYan Peng3, HuiYu Sun4.
Abstract
BACKGROUND: Studies investigating the associations between transcription factor 4 (TCF4) genetic polymorphisms and Fuchs' endothelial dystrophy (FED) have reported controversial results. Therefore, this meta-analysis aims to clarify the effects of TCF4 polymorphisms on FED risk.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26087656 PMCID: PMC4474332 DOI: 10.1186/s12886-015-0055-6
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Fig. 1Flow diagram outlining the selection process for inclusion of studies in the systematic review and meta-analysis
Characteristics of included studies
| First Author (year) | Country | Ethnicity | Study design | Genotyping method | Case/Control | Source of control | SNP | HW-E test |
|---|---|---|---|---|---|---|---|---|
| Baratz (2010)a [ | USA | Caucasian | GWAS | Taqman assay | 130/260 | HB | rs613872,rs17595731, | yes |
| rs9954153,rs2286812 | ||||||||
| Baratz (2010)b [ | USA | Caucasian | GWAS | Taqman assay | 150/150 | HB | rs613872,rs17595731, | yes |
| rs9954153,rs2286812 | ||||||||
| Li (2011) [ | USA | Caucasian | Case–control | Taqman assay | 450/340 | HB | rs613872 | yes |
| Riazuddin (2011) [ | USA | Caucasian | Case–control | Taqman assay | 170/180 | HB | rs613872 | yes |
| Thalamuthu (2011) [ | Singapore | Asian | Case–control | MassArray | 57/121 | HB | rs2286812 | yes |
| Igo (2012) [ | USA | Caucasian | Case–control | Taqman assay | 531/204 | HB | rs613872 | no |
| Kuot (2012) [ | Australia | Caucasian | Case–control | MassArray | 103/275 | HB | rs613872,rs9954153, | yes |
| rs2286812,rs17595731 | ||||||||
| Stamler (2013) [ | USA | Caucasian | Case–control | Taqman assay | 82/163 | HB | rs613872 | yes |
| Nanda (2014) [ | India | Asian | Case–control | PCR-sequencing | 44/108 | HB | rs613872 | yes |
| Wang (2014) [ | China | Asian | Case–control | Taqman assay | 34/491 | HB | rs2286812 | yes |
| Li (2014) [ | USA | Caucasian | Case–control | Taqman assay | 529/494 | HB | rs613872 | yes |
| Mootha (2014) [ | USA | Caucasian | Case–control | Taqman assay | 120/100 | HB | rs613872 | yes |
| Wieben (2014) [ | USA | Caucasian | Case–control | PCR-sequencing | 68/16 | HB | rs613872 | yes |
HW-E Hardy Weinberg equilibrium; PCR polymerase chain reaction; HB hospital-based
aThe data extracted from discovery group
bThe data extracted from replication group
Results of meta-analysis for TCF4 polymorphisms and risk of FED
| Polymorphism (comparison) | No. of studies | OR (95%CI) |
| Heterogeneity |
|
| ||
|---|---|---|---|---|---|---|---|---|
|
| I2 |
| ||||||
| rs613872 | ||||||||
| G vs. T | 10 | 4.19(3.53–4.97) | <0.001 | 16.60 | 45.8 % | 0.055 | 0.411 | 0.474 |
| GG vs. GT/TT | 6 | 4.27(2.54–7.19) | <0.001 | 6.20 | 19.3 % | 0.288 | 0.295 | 0.260 |
| GG/GT vs. TT | 7 | 6.29(4.23–8.93) | <0.001 | 16.23 | 63.0 % | 0.013 | 0.586 | 0.707 |
| GG VS. TT | 6 | 10.64(5.28–21.41) | <0.001 | 9.43 | 47.0 % | 0.093 | 0.378 | 0.452 |
| GT VS. TT | 6 | 6.08 (4.28–8.64) | <0.001 | 12.72 | 60.7 % | 0.026 | 0.938 | 0.707 |
| rs2286812 | ||||||||
| T vs C | 5 | 1.77(1.19–2.63) | 0.005 | 12.10 | 66.9 % | 0.017 | 0.207 | 0.180 |
| rs17595731 | ||||||||
| C vs G | 3 | 4.70(3.06–7.21) | <0.001 | 1.27 | 0.0 % | 0.530 | 0.775 | 1.000 |
| rs9954153 | ||||||||
| G vs T | 3 | 2.43(1.97–3.01) | <0.001 | 0.20 | 0.0 % | 0.906 | 0.793 | 1.000 |
TCF4 transcription factor 4; FED Fuchs endothelial dystrophy; OR odds ratio; CI confidence Interval
a P Egger’s test = the P value for Egger’s test
b P Begg’s test = the P value for Begg’s test
Fig. 2Forest plot for the association between TCF4 rs613872 polymorphism and FED risk (G allele vs. T allele). OR: odds ratio; CI: confidence interval; TCF4: transcription factor 4; FED: Fuchs endothelial dystrophy
Sensitivity analysis of the meta-analysis results for TCF4 rs613872 polymorphism and FED risk (G allele vs. T allele)
| Random effects model | Test of homogeneity | ||||
|---|---|---|---|---|---|
| Study Excluded | OR | 95%CI | Q | I2 (%) |
|
| None | 4.19 | 3.53–4.97 | 16.60 | 45.8 | 0.055 |
| Baratz (2010)a [ | 4.23 | 3.52–5.09 | 16.22 | 50.7 | 0.039 |
| Baratz (2010)b [ | 4.19 | 3.48–5.04 | 16.58 | 51.8 | 0.035 |
| Li (2011) [ | 4.26 | 3.50–5.19 | 15.12 | 47.1 | 0.057 |
| Riazuddin (2011) [ | 4.16 | 3.43–5.04 | 16.59 | 51.8 | 0.035 |
| Igo (2012) [ | 4.11 | 3.41–4.96 | 16.20 | 50.6 | 0.040 |
| Kuot (2012) [ | 4.19 | 3.46–5.09 | 16.53 | 51.6 | 0.035 |
| Stamler (2013) [ | 4.21 | 3.48–5.08 | 16.46 | 51.4 | 0.036 |
| Nanda (2014) [ | 4.38 | 3.89–4.94 | 7.69 | 0.0 | 0.464 |
| Li (2014) [ | 4.01 | 3.37–4.78 | 12.57 | 51.4 | 0.042 |
| Mootha (2014) [ | 4.05 | 3.42–4.80 | 13.78 | 41.9 | 0.088 |
TCF4 transcription factor 4; FED Fuchs’ endothelial dystrophy; OR odds ratio; CI confidence Interval
aThe data extracted from discovery group
bThe data extracted from replication group
Fig. 3Funnel plot for studies of the association of TCF4 rs613872 polymorphism and FED risk (G allele vs. T allele). OR: odds ratio; TCF4: transcription factor 4; FED: Fuchs endothelial dystrophy